ACT has successfully completed Phase I, open label, dose escalation, multicenter clinical trial in patients with advanced solid tumors. The study evaluated the safety, tolerability and antitumor activity of PFK158, a small molecule therapeutic candidate. The centers involved with the study are the MD Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, the Lombardi Cancer Center at Georgetown
University and the Brown Cancer Center at the University of Louisville.
Advanced Cancer Therapeutics